# EDGAR Filing Document

**Accession Number:** 0000096943
**File Stem:** 0000096943-26-000011
**Filing Date:** 2026-2
**Character Count:** 120981
**Document Hash:** 7c18beb9fe191d3c4edd64ea3ee41bb3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000096943-26-000011.hdr.sgml**: 20260226

**ACCESSION NUMBER**: 0000096943-26-000011

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 51

**CONFORMED PERIOD OF REPORT**: 20260223

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Cost Associated with Exit or Disposal Activities

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260226

**DATE AS OF CHANGE**: 20260226

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TELEFLEX INC
- **CENTRAL INDEX KEY:** 0000096943
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 231147939
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-05353
- **FILM NUMBER:** 26681629

**BUSINESS ADDRESS:**
- **STREET 1:** 550 E SWEDESFORD RD
- **STREET 2:** SUITE 400
- **CITY:** WAYNE
- **STATE:** PA
- **ZIP:** 19087
- **BUSINESS PHONE:** 610-225-6800

**MAIL ADDRESS:**
- **STREET 1:** 550 E SWEDESFORD RD
- **STREET 2:** SUITE 400
- **CITY:** WAYNE
- **STATE:** PA
- **ZIP:** 19087

?xml version='1.0' encoding='ASCII'? tfx-20260223

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K** 

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

---

| | |
|:---|:---|
| **Date of Report (Date of Earliest Event Reported)** | **February 23, 2026** |

---

**TELEFLEX INCORPORATED** 

(Exact name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **<u>Delaware</u>** | **<u>1-5353</u>** | **<u>23-1147939</u>** |
| (State or Other Jurisdiction<br>of Incorporation or Organization) | (Commission File Number) | (IRS Employer<br>Identification No.) |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **<u>550 E. Swedesford Rd., Suite 400</u>** | **<u>Wayne,</u>** | **<u>PA</u>** |  | **<u>19087</u>** |
| **(Address of Principal Executive Offices)** | **(Address of Principal Executive Offices)** | **(Address of Principal Executive Offices)** |  | (Zip Code) |
| Registrant's Telephone Number, Including Area Code |  | **(610)** | **225-6800** |  |

---

---

| |
|:---|
| **Not applicable** |
| **(Former Name or Former Address, If Changed Since Last Report)** |

---

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $1 per share | TFX | New York Stock Exchange |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02. Results of Operations and Financial Condition.** 

*Earnings Press Release*

On February 26, 2026, Teleflex Incorporated (the "Company") issued a press release (the "Press Release") announcing its financial results for the year ended December 31, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report.

In addition to the financial information included in the Press Release that has been prepared in accordance with generally accepted accounting principles in the United States ("GAAP"), the Press Release includes certain non-GAAP financial measures. These measures include adjusted revenue growth, adjusted constant currency revenue growth, pro forma adjusted revenues, pro forma adjusted constant currency revenue growth and adjusted diluted earnings per share. Adjusted revenue is based upon net revenues, adjusted to exclude the impact of an increase in reserves for prior years. The reserve, which relates to legislation that requires suppliers of medical devices to the Italian National Healthcare System to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year, was increased as a result of a recent ruling from the Italian courts. The amounts related to the prior years do not represent normal adjustments to revenue, are not expected to recur in future periods and are not recurring in nature, making it difficult to contribute to a meaningful evaluation of our operating performance. Adjusted constant currency revenue growth is based upon net revenues, adjusted to eliminate the impacts related to the Italian payback measure referred to above and of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and generally are outside of the control of our management. Pro forma adjusted revenue is based upon net revenues, adjusted to (i) exclude, depending on the period presented, the impact of adjustments in our reserves and the corresponding revenue impact related to the Italian payback measure described in adjusted revenue and approximately $14 million of products discontinued in the year ended December 31, 2025 due to a strategic realignment; and (ii) include revenues for the six months ended June 29, 2025 generated by the Vascular Intervention business we acquired from BIOTRONIK SE & Co. KG. Pro forma adjusted constant currency revenue growth is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Pro forma adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. We believe that these measures facilitate a comparison of our operating performance exclusive of fluctuations that do not reflect our underlying performance or business trends. Adjusted diluted earnings per share is based upon diluted earnings per share available to common stockholders, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the impact (net of tax) of (i) restructuring and optimization charges; (ii) impairment charges, (iii) acquisition, integration and divestiture related items; (iv) separation costs related to the Company's entry into agreements to divest its Acute Care, Interventional Urology and OEM businesses (the "Strategic Divestitures"), including activities to prepare the businesses for divestiture and maintain continuity through the separation process; (v) the impact from increases in our reserves related to the Italian payback measure pertaining to prior years as described in adjusted revenue; (vi) other items identified in the reconciliation tables set forth in the Press Release, as applicable; (vii) pension termination and related charges; (viii) certain expenditures associated with the registration of medical devices under the European Union Medical Device Regulation; (ix) intangible amortization expense; (x) costs incurred in connection with our implementation of a new global enterprise resource planning system and related information technology transition costs; and (xi) tax adjustments. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.

Management uses these non-GAAP financial measures to assess the Company's financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management's assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies.

------

*Supplemental Financial Information*

The information set forth under Item 7.01 "Regulation FD Disclosure" concerning the Supplemental Financial Information (as defined therein) is incorporated herein by reference.

The information furnished pursuant to Item 2.02 of this Current Report, including Exhibit 99.1 hereto and the Supplemental Financial Information set forth under Item 7.01 incorporated herein by reference, shall not be considered "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.

**Item 2.05 Costs Associated with Exit or Disposal Activities.**

On February 23, 2026, in connection with the Strategic Divestitures, the Company's Board of Directors approved a multi-year restructuring plan intended to align the Company's global organizational structure and supply chain infrastructure amongst its remaining businesses. The plan is designed to eliminate stranded costs, streamline global operations, and improve the Company's long-term cost structure, primarily through workforce reductions and capital assets rationalization. These actions, some of which are expected to occur upon exit of the transition services agreements and other arrangements negotiated in connection with the Strategic Divestitures, are expected to be substantially completed by mid-2028. The following table provides a summary of the Company's estimates of restructuring and restructuring related charges by major type of expense associated with the Strategic Divestitures restructuring plan:

---

| | |
|:---|:---|
| | **Strategic Divestiture restructuring plan** |
| **Plan expense estimates:** | **(Dollars in millions)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring charges (1) | $15 million to $18 million |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring related charges (2)  | $16 million to $19 million |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total restructuring and restructuring related charges | $31 million to $37 million |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Substantially all of the charges consist of employee termination benefit costs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Restructuring related charges represent costs that are directly related to the plan and primarily include expenses related to a lease termination and retention incentives necessary to support critical functions during the transition period. Most of the charges are expected to be recognized within selling, general and administrative costs.

The Company expects substantially all the restructuring and restructuring related charges to result in future cash outlays, of which, an estimated $15.0 million to $19.0 million are expected to occur during 2026. The Company expects to achieve annual pre-tax savings of $48 million to $52 million in connection with the Strategic Divestitures restructuring plan once it is fully implemented and expects to begin realizing a portion of these plan-related savings in 2026.

**Item 7.01. Regulation FD Disclosure.**

In connection with the conference call to be held by the Company on February 26, 2026 to discuss its financial results for the year ended December 31, 2026, the Company plans to reference a slide presentation, which will be made available in advance of the call through the Company's website. A copy of the slide presentation is furnished as Exhibit 99.2 to this Current Report.

The slide presentation attached hereto as Exhibit 99.2 includes supplemental financial information (the "Supplemental Financial Information") that provides GAAP to non-GAAP reconciliation tables with respect to consolidated statement of income items for the quarters ended March 30, 2025, June 29, 2025 and September 28, 2025. The Supplemental Financial Information has been adjusted to exclude the results of businesses that have been reclassified as discontinued operations, which will be divested by the Company through the Strategic Divestitures. The Supplemental Financial Information includes non-GAAP financial measures, which we believe facilitate an

------

understanding of our past operating performance exclusive of businesses that will no longer impact our operating performance in future periods, and thus will enable more meaningful comparisons between past and future periods.

The information furnished pursuant to Item 7.01 of this Current Report, including Exhibit 99.2, shall not be considered "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.

**Item 9.01. Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1&nbsp;&nbsp;&nbsp;&nbsp;<u>[Press Release, dated](ex991to2-26x2026re2025yeea.htm)[February 2](ex991to2-26x2026re2025yeea.htm)[6, 202](ex991to2-26x2026re2025yeea.htm)[6](ex991to2-26x2026re2025yeea.htm)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.2&nbsp;&nbsp;&nbsp;&nbsp;<u>[Earnings Conference Call Slide Presentation](exhibit992to2-26x2026re2.htm)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;104&nbsp;&nbsp;&nbsp;&nbsp;The Cover Page from this Current Report on Form 8-K, formatted in Inline XBRL

------

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.&nbsp;&nbsp;&nbsp;&nbsp;

---

| | |
|:---|:---|
| Date: February 26, 2026 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TELEFLEX INCORPORATED<br>By: <u>/s/ John R. Deren</u> <br>Name: John R. Deren<br>Title: Executive Vice President and Chief Financial Officer |

---

## Exhibit 99.1

Exhibit 99.1

![tfxlogoa.jpg](tfxlogoa.jpg)

FOR IMMEDIATE RELEASE February 26, 2026

**Teleflex Reports 2025 Financial Results and Full Year 2026 Outlook**

*Announces Restructuring to Right-Size and Reduce Cost Structure Related to Announced Strategic Divestitures*

**Wayne, PA --** Teleflex Incorporated (NYSE: TFX) (the "Company") today announced financial results for the year ended December 31, 2025.

***Full year 2025 continuing operations financial summary***<sup>1</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• GAAP revenue from continuing operations of $1,992.7 million, up 17.2% compared to the prior year period*<sup>1</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*◦ Adjusted revenue from continuing operations of $1,983.7 million, up 16.3% compared to the prior year period, and up 15.4% on an adjusted constant currency basis*<sup>2</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• GAAP diluted EPS from continuing operations of $1.31, compared to $1.21 in the prior year period*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Adjusted diluted EPS from continuing operations of $6.98, compared to $6.42 in the prior year period*

***2026 continuing operations guidance summary***<sup>1</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• GAAP revenue growth guidance range of 14.40% to 15.40%*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Pro forma adjusted constant currency revenue growth guidance range of 4.50% to 5.50%*<sup>3</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• GAAP EPS from continuing operations guidance range to $2.90 to $3.20*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Adjusted diluted EPS from continuing operations guidance range to $6.25 to $6.55*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*◦ Includes full year impact of stranded costs estimated to be $90 million*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ *Excludes expected benefits from transition services ("TS") and manufacturing services ("MS") agreements that come into effect upon closing of Strategic Divestitures, which we anticipate will fully offset stranded costs on an annualized basis*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*◦ Excludes impact of repurchases under previously announced $1 billion share repurchase program and expected debt paydown of ~$800 million upon closing of Strategic Divestitures* 

"Teleflex is in the midst of a transformation that optimizes our portfolio, creates a more focused medical technologies leader and positions our company for meaningful value creation opportunities going forward," said Stuart Randle, Teleflex's Interim President and Chief Executive Officer. "It is energizing to see how focused and committed our team has been to delivering for customers, patients, and shareholders. We have introduced financial guidance for 2026, which calls for mid-single-digit pro forma adjusted constant currency revenue growth. Our 2026 adjusted EPS outlook includes the full impact of stranded costs and excludes benefits from TS and MS agreements, share repurchase under our current $1 billion share repurchase authorization and intended debt paydown from the estimated $1.8 billion in after-tax proceeds from the strategic divestitures.

------

We expect the TS and MS agreements to fully offset the $90 million in stranded costs on an annualized basis. Furthermore, we are already taking action on reducing expenses when the TS and MS agreements roll off in the future, and are announcing an initial restructuring plan to mitigate $48 million to $52 million of annual stranded costs resulting from the divestitures."

Mr. Randle continued, "We expect our two strategic divestitures to close in the second half of 2026 and remain committed to using the majority of the net proceeds from the transactions to return significant capital to shareholders through share repurchases, while also reducing debt to enhance our financial flexibility and support future growth and value creation. With a more streamlined portfolio and clear strategic priorities, we believe we will be well positioned to drive durable performance and long-term value for shareholders."

***STRATEGIC DIVESTITURES RESTRUCTURING PLAN***

In the first quarter of 2026, in connection with the Strategic Divestitures, our Board of Directors approved and we commenced a multi-year restructuring plan intended to align our global organizational structure and supply chain infrastructure amongst our remaining businesses. The right-sizing plan is designed to eliminate stranded costs, streamline global operations, and improve our long-term cost structure, primarily through workforce reductions and capital assets rationalization. These actions, some of which we expect to occur upon exit of the transition services agreements and other arrangements negotiated in connection with the Strategic Divestitures, are expected to be substantially completed by mid-2028.

We expect to achieve annual pre-tax savings of $48 million to $52 million in connection with the restructuring plan once it is fully implemented, and we expect to begin realizing a portion of these plan-related savings in 2026.

***SECOND HALF 2025 CONTINUING OPERATIONS FINANCIAL SUMMARY***<sup>1</sup>

GAAP revenue growth of 30.8% compared to the prior period

Pro forma adjusted constant currency revenue growth of 4.7% compared to the prior year period, reflecting the period during 2025 in which Teleflex owned the Vascular Intervention business<sup>3</sup>

*(1) Continuing operations excludes the Acute Care, Interventional Urology, and OEM businesses that were classified as discontinued operations during the fourth quarter of 2025 as a result of our entry into agreements to divest those businesses, which we refer to as the "Strategic Divestitures".* 

*(2) Adjusted revenue excludes the impact of adjustments in our reserves related to the Italian payback measure. Refer to Notes on Non-GAAP Financial Measures for detail on the Italian payback measure.*

*(3) Pro forma adjusted constant currency revenue growth includes revenue generated by the acquired Vascular Intervention business in the prior year period, and excludes (a) revenue generated by products previously included within continuing operations that were discontinued at the end of 2025 due to a strategic realignment, (b) the Italian payback measure and (c) the impact of foreign exchange.*

*Restated historical results reflecting the Acute Care, Interventional Urology, and OEM businesses as discontinued operations for 2025 can be found in the appendix of our slides that accompany our year-end 2025 earnings conference call.*

------

**PRO FORMA ADJUSTED REVENUE BY GLOBAL PRODUCT CATEGORY**

The following table provides information regarding pro forma adjusted revenues in each of the Company's global product categories in continuing operations in addition to pro forma adjusted constant currency revenues and revenue growth for specified periods in 2025.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **FY 2025** | **Q4 2025** | **Q3 2025** | **Q2 2025** | **Q1 2025** |
| Vascular | 917.7 | 240.2 | 232.5 | 225.9 | 219.1 |
| Interventional | 647.8 | 217.9 | 215.9 | 113.8 | 100.2 |
| Surgical | 418.2 | 110.9 | 109.5 | 102.8 | 95.0 |
| Other | 9.0 |  | 9.0 |  |  |
| GAAP revenue | 1992.7 | 569.0 | 566.9 | 442.5 | 414.3 |
| Interventional - Vascular Intervention | 199.0 |  |  | 103.8 | 95.2 |
| Interventional - Discontinued Products | (12.3) | (1.3) | (5.0) | (3.4) | (2.6) |
| Surgical - Discontinued Products | (2.0) | (0.4) | (0.6) | (0.5) | (0.5) |
| Other - Italian payback measure | (9.0) |  | (9.0) |  |  |
| Pro forma adjusted revenue | $2168.3 | $567.3 | $552.2 | $542.4 | $506.4 |
| &nbsp;&nbsp;&nbsp;Vascular | 917.7 | 240.2 | 232.5 | 225.9 | 219.1 |
| &nbsp;&nbsp;&nbsp;Interventional | 834.5 | 216.6 | 210.9 | 214.2 | 192.8 |
| &nbsp;&nbsp;&nbsp;Surgical | 416.1 | 110.5 | 108.8 | 102.3 | 94.5 |
| &nbsp;&nbsp;&nbsp;Other |  |  |  |  |  |

---

---

| | | | |
|:---|:---|:---|:---|
| | **Pro Forma Adjusted Constant Currency Revenue Growth** | **Pro Forma Adjusted Constant Currency Revenue Growth** | **Pro Forma Adjusted Constant Currency Revenue Growth** |
| | **2H 2025** | **Q4 2025** | **Q3 2025** |
| Vascular | 2.4% | 3.4% | 1.4% |
| Interventional | 8.1% | 8.2% | 8.0% |
| Surgical | 3.2% | (0.7)% | 7.5% |
| Pro forma adjusted revenue | 4.7% | 4.3% | 5.0% |

---

**Reconciliation of Revenues (Dollars in millions)** 

---

| | |
|:---|:---|
| | **Year Ended** |
| | **December 31, 2025** |
| GAAP revenue including discontinued operations | $3297.0 |
| &nbsp;&nbsp;&nbsp;Discontinued operations | (1304.3) |
| Continuing operations | 1992.7 |
| &nbsp;&nbsp;Italian payback measure adjustment | (9.0) |
| Adjusted revenues from continuing operations | $1983.7 |

---

**OTHER CONTINUING OPERATIONS FINANCIAL HIGHLIGHTS** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Depreciation expense, amortization of intangible assets and deferred financing charges for the year ended December 31, 2025 totaled $182.4 million compared to $164.9 million for the prior year period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total cash, cash equivalents and restricted cash equivalents at December 31, 2025 were $402.7 million compared to $285.3 million at December 31, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net accounts receivable at December 31, 2025 were $345.6 million compared to $226.7 million at December 31, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Inventories at December 31, 2025 were $404.4 million compared to $306.8 million at December 31, 2024.

------

**2026 CONTINUING OPERATIONS OUTLOOK** 

On a GAAP basis, the Company expects full year 2026 revenue growth from continuing operations of 14.40%% to 15.40%%, including our estimate of an approximately 0.70% positive impact of foreign exchange rate fluctuations. On a pro forma adjusted constant currency basis, the Company expects full year 2026 revenue growth from continuing operations of 4.50% to 5.50%.

***Forecasted 2026 Pro Forma Adjusted Constant Currency Revenue Growth From Continuing Operations Reconciliation***

---

| | | | |
|:---|:---|:---|:---|
| | **2025** | **2026 Guidance** | **2026 Guidance** |
| | **2025** | **Low** | **High** |
| GAAP revenue | $1992.7 | $2280 | $2300 |
| &nbsp;&nbsp;&nbsp;*% growth* |  | *14.4%* | *15.4%* |
| Vascular Intervention pro forma adjustment | $199.0 |  |  |
| Discontinued product adjustment | $(14.3) |  |  |
| Italian payback measure adjustment | $(9.0) |  |  |
| Pro forma adjusted revenue | $2168.4 | $2280 | $2300 |
| &nbsp;&nbsp;&nbsp;*% growth* |  | *5.1%* | *6.1%* |
| &nbsp;&nbsp;&nbsp;*Base year adjustment (GAAP versus pro forma adjusted)* |  | *0.1%* | *0.1%* |
| &nbsp;&nbsp;&nbsp;*% growth* |  | *5.2%* | *6.2%* |
| &nbsp;&nbsp;&nbsp;*Estimated impact of foreign currency exchange rate fluctuations* |  | *(0.7)%* | *(0.7)%* |
| % pro forma adjusted constant currency revenue growth |  | 4.5% | 5.5% |

---

The Company expects full year 2026 GAAP diluted earnings per share from continuing operations outlook of $2.90 to $3.20. The Company expects full year 2026 adjusted diluted earnings per share from continuing operations of $6.25 to $6.55.

***Forecasted 2026 Pro Forma Adjusted Constant Currency Revenue Percent Growth From Continuing Operations Reconciliation***

---

| | | |
|:---|:---|:---|
| | **Low** | **High** |
| Forecasted 2026 GAAP revenue growth | 14.4% | 15.4% |
| Vascular Intervention pro forma adjustment | 10.0% | 10.0% |
| Discontinued product adjustment | (0.7)% | (0.7)% |
| Italian payback measure adjustment | (0.5)% | (0.5)% |
| Base year adjustment (GAAP versus pro forma adjusted) | 0.4% | 0.4% |
| Estimated impact of foreign currency exchange rate fluctuations | 0.7% | 0.7% |
| Forecasted 2026 pro forma adjusted constant currency revenue growth | 4.5% | 5.5% |

---

------

***Forecasted 2026 Adjusted Diluted Earnings Per Share From Continuing Operations Reconciliation***

---

| | | |
|:---|:---|:---|
| | **Low** | **High** |
| Forecasted GAAP diluted earnings per share from continuing operations | $2.90 | $3.20 |
| Restructuring and optimization items, net of tax | $0.81 | $0.81 |
| Acquisition, integration and divestiture related items, net of tax | $0.76 | $0.76 |
| Other items, net of tax | $(0.65) | $(0.65) |
| ERP implementation, net of tax | $0.33 | $0.33 |
| MDR, net of tax | $0.03 | $0.03 |
| Intangible amortization expense, net of tax | $2.07 | $2.07 |
| Forecasted adjusted diluted earnings per share from continuing operations, net of tax | $6.25 | $6.55 |

---

------

**CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION**

A webcast of Teleflex's year-end 2025 investor conference call can be accessed live from a link on the Company's website at teleflex.com. The call will begin at 8:00 am ET on February 26, 2026.

An audio replay of the investor call will be available beginning at 11:00 am ET on February 26, 2026, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909(all other locations). The confirmation code is 69028.

**ADDITIONAL NOTES**

References in this release to the impact of foreign currency exchange rate fluctuations on adjusted diluted earnings per share include both the impact of translating foreign currencies into U.S. dollars and the impact of foreign currency exchange rate fluctuations on foreign currency denominated transactions.

In the discussion of segment results, "new products" refers to products for which we initiated commercial sales within the past 36 months and "existing products" refers to products we have sold commercially for more than 36 months.

Certain financial information is presented on a rounded basis, which may cause minor differences. Segment results and commentary exclude the impact of discontinued operations.

**NOTES ON NON-GAAP FINANCIAL MEASURES**

We report our financial results in accordance with accounting principles generally accepted in the United States, commonly referred to as "GAAP". In this press release, we provide supplemental information, consisting of the following non-GAAP financial measures: adjusted revenue, adjusted constant currency revenue growth, pro forma adjusted revenues, pro form adjusted constant currency revenue growth, and adjusted diluted earnings per share. These non-GAAP measures are described in more detail below. Management uses these financial measures to assess Teleflex's financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management's assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies.

Tables reconciling changes in historical adjusted constant currency net revenues and adjusted net revenues to historical GAAP net revenues and historical adjusted diluted earnings per share from continuing operations to historical GAAP diluted earnings per share from continuing operations are set forth below.

**Adjusted revenue:** This non-GAAP measure is based upon net revenues, adjusted to exclude the impact of adjustments in our reserves and the corresponding revenue impact related to the Italian payback measure. The Italian payback measure is a law that requires suppliers of medical devices to the Italian National Healthcare System to make

------

payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year.

As a result of a ruling from the Italian courts, we recognized a decrease in our reserves during the year ended December 31, 2024, of which $13.8 million related to prior years when including discontinued operations and $6.2 million on a continuing operations basis.

In August 2025, the Italian Parliament enacted a modification to the previously enacted legislation that reduced the payment amounts due from the affected companies, including Teleflex, to approximately 25% of the amounts originally invoiced for the years 2015 through 2018. Payment of the reduced amount precludes the pursuit of further legal action related to the obligation to pay the amounts relating to such years. During the third quarter of 2025, we remitted payment to the related regions to settle the years 2015 through 2018. As a result of the modification in the legislation, along with an adjustment to our calculation of the reserves related to years 2019 through 2025, we recognized a $23.7 million decrease in our reserve (and corresponding increase to revenue for the three months and year ended December 31, 2025), of which $20.1 million pertains to prior periods when including discontinued operations and $9.0 million on a continuing operations basis.

The amounts do not represent normal adjustments to revenue and are nonrecurring in nature, making it difficult to contribute to a meaningful evaluation of our period over period operating performance. Accordingly, management has excluded the $9.0 million favorable adjustment recognized in the current period and the unfavorable adjustment of $6.2 million in the prior period.

**Adjusted constant currency revenue growth:** This non-GAAP measure is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends.

**Pro forma adjusted revenue:** This non-GAAP measure is based upon net revenues, adjusted to (i) exclude, depending on the period presented, the impact of adjustments in our reserves and the corresponding revenue impact related to the Italian payback measure described in Adjusted revenue and approximately $14 million of products discontinued in the year ended December 31, 2025 due to a strategic realignment; and (ii) include revenues for the six months ended June 29, 2025 generated by the Vascular Intervention business we acquired from BIOTRONIK SE & Co. KG.

**Pro forma adjusted constant currency revenue growth:** This non-GAAP measure is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Pro forma adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison

------

of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends.

**Adjusted diluted earnings per share:** This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the items described below. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.

*Restructuring and optimization charges* - Restructuring and optimization charges include expenses associated with discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies, integrate acquired businesses and optimize product portfolios through targeted optimization efforts. These changes include qualified restructuring costs (which may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement), restructuring related (which may include accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of a restructuring program) and product line exit charges.

*Impairment charges* - Impairment charges, including those related to goodwill, and other assets occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results.

*Acquisition, integration and divestiture related items -* Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; temporary financing costs directly associated with the transaction, such as bridge loan financing fees, ticking fees, and similar charges, and the impact of derivative instruments executed to hedge foreign currency exposure or other risks associated with the purchase price. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities.

S*eparation costs -* These are expenses related to the Strategic Divestitures, including activities to prepare the businesses for divestiture and maintain continuity through the separation process. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur after the transaction and related transition services agreements and other arrangements negotiated in connection with the Strategic Divestitures have been completed.

*Italian payback measure -* These adjustments represent the exclusion of adjustments in our reserves related to the Italian payback measure as described in Adjusted revenue.

------

*Other -* These are discrete items that occur sporadically and can affect period-to-period comparisons.

*Pension termination and related charges -* These adjustments represent charges associated with the planned termination of the Teleflex Incorporated Retirement Income Plan, a frozen U.S. defined benefit pension plan, and related direct incremental expenses including certain charges stemming from the liquidation of surplus plan assets. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur once the plan termination process has been completed. Accordingly, management has excluded these amounts to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

*European medical device regulation -* The European Union ("EU") has adopted the EU Medical Device Regulation ("MDR"), which replaces the existing Medical Devices Directive ("MDD") and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post-market surveillance. The MDR requirements became effective in May 2021, although certain devices that previously satisfied MDD requirements can continue to be marketed in the EU until December 2027 for highest-risk devices and December 2028 for lower-risk devices, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices. As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD).

*Intangible amortization expense -* Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions.

*ERP implementation -* These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance.

*Tax adjustments -* These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability.

------

**Reconciliation of Revenue Growth**

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2H 2025** | **2H 2025** | **2H 2025** | **2H 2025** | **Q4 2025** | **Q4 2025** | **Q4 2025** | **Q4 2025** | **Q3 2025** | **Q3 2025** | **Q3 2025** | **Q3 2025** |
| | Reported Revenue Growth | Currency Impact | Adjustment Impact | Pro Forma Adjusted Constant Currency Revenue Growth | Reported Revenue Growth | Currency Impact | Adjustment Impact | Pro Forma Adjusted Constant Currency Revenue Growth | Reported Revenue Growth | Currency Impact | Adjustment Impact | Pro Forma Adjusted Constant Currency Revenue Growth |
| Vascular | 4.2% | (1.8)% | —% | 2.4% | 5.6% | (2.2)% | —% | 3.4% | 2.7% | (1.3)% | —% | 1.4% |
| Interventional<sup>1</sup> | 113.4 | (2.8) | (102.5) | 8.1 | 108.7 | (3.4) | (97.1) | 8.2 | 118.5 | (2.2) | (108.3) | 8.0 |
| Surgical<sup>2</sup> | 4.4 | (1.5) | 0.3 | 3.2 | 0.6 | (1.7) | 0.4 | (0.7) | 8.4 | (1.1) | 0.2 | 7.5 |
| Total Continuing Operations<sup>3</sup> | 30.8% | (2.0)% | 24.1% | 4.7% | 28.7% | (2.4)% | 22.0% | 4.3% | 33.0% | (1.5)% | 26.5% | 5.0% |

---

Notes: (1) Adjustments are inclusive of Vascular Intervention pro forma and discontinued product adjustments for all periods presented

&nbsp;&nbsp;&nbsp;&nbsp;(2) Adjustments are inclusive of discontinued product adjustments for all periods presented

&nbsp;&nbsp;&nbsp;&nbsp;(3) Adjustments are inclusive of Vascular Intervention pro forma, Italian payback measure, and discontinued product adjustments for all periods presented

**Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** |
| | **Revenue** | **Gross margin** | **SG&A (1)** | **R&D (1)** | **Operating margin (2)** | **(Loss) Income before income taxes** | **Income tax expense** | **Effective income tax rate** | **Diluted (loss) earnings per share from continuing operations** |
| GAAP Basis - Continuing Operations | $569.0 | 54.0% | 39.1% | 8.6% | 2.4% | $(12.4) | $(8.9) | 71.4% | $(0.08) |
| **Adjustments** |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Restructuring and optimization charges (A) |  | 0.7 |  |  | 4.3 | 24.3 | 3.9 |  | 0.46 |
| &nbsp;&nbsp;Acquisition, integration and divestiture related items (B) |  | 4.8 | (1.9) |  | 6.7 | 37.6 | 6.8 |  | 0.69 |
| &nbsp;&nbsp;Separation costs |  |  |  |  | 0.4 | 2.2 | 1.1 |  | 0.03 |
| &nbsp;&nbsp;ERP implementation |  |  | (1.1) |  | 1.1 | 6.3 | 1.2 |  | 0.12 |
| &nbsp;&nbsp;MDR |  |  |  | (0.3) | 0.2 | 1.4 |  |  | 0.03 |
| &nbsp;&nbsp;Intangible amortization expense |  | 3.3 | (3.1) |  | 6.4 | 36.7 | 4.8 |  | 0.72 |
| &nbsp;&nbsp;Tax adjustments |  |  |  |  |  |  | 1.7 |  | (0.04) |
| &nbsp;&nbsp;Adjustments total |  | 8.8 | (6.1) | (0.3) | 19.1 | 108.5 | 19.5 |  | 2.01 |
| **Adjusted basis** | **$569.0** | **62.8%** | **33.0%** | **8.3%** | **21.5%** | **$96.1** | **$10.6** | **11.1%** | **$1.93** |

---

------

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** |
| | **Revenue** | **Gross margin** | **SG&A (1)** | **R&D (1)** | **Operating margin (2)** | **Income before income taxes** | **Income tax expense** | **Effective income tax rate** | **Diluted earnings per share from continuing operations** |
| GAAP Basis - Continuing Operations | $442.0 | 60.8% | 40.3% | 6.6% | 11.9% | $35.5 | $(0.4) | (1.1)% | $0.77 |
| **Adjustments** |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Restructuring and optimization charges (A) |  | 1.0 |  |  | 3.0 | 7.6 | 1.2 |  | 0.14 |
| &nbsp;&nbsp;Impairment charges |  |  |  |  |  | 5.7 |  |  | 0.12 |
| &nbsp;&nbsp;Acquisition, integration and divestiture related items (B) |  |  | (2.3) |  | 2.3 | 10.2 | 0.5 |  | 0.20 |
| &nbsp;&nbsp;Other items (C) |  |  | (0.2) |  | 0.2 | 1.0 | 0.2 |  | 0.02 |
| &nbsp;&nbsp;ERP implementation |  |  | (0.8) |  | 0.8 | 3.5 | 0.4 |  | 0.07 |
| &nbsp;&nbsp;MDR |  |  |  | (0.1) | 0.1 | 0.4 |  |  | 0.01 |
| &nbsp;&nbsp;Pension termination costs |  | 0.6 | (0.7) | (0.2) | 1.5 | 6.5 | 1.5 |  | 0.11 |
| &nbsp;&nbsp;Intangible amortization expense |  | 3.4 | (2.7) |  | 6.1 | 27.3 | 2.9 |  | 0.52 |
| &nbsp;&nbsp;Tax adjustments |  |  |  |  |  |  | 2.3 |  | (0.05) |
| &nbsp;&nbsp;Adjustments total |  | 5.0 | (6.7) | (0.3) | 14.0 | 62.2 | 9.0 |  | 1.14 |
| **Adjusted basis** | **$442.0** | **65.8%** | **33.6%** | **6.3%** | **25.9%** | **$97.7** | **$8.6** | **8.8%** | **$1.91** |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Year Ended December 31, 2025** | **Year Ended December 31, 2025** | **Year Ended December 31, 2025** | **Year Ended December 31, 2025** | **Year Ended December 31, 2025** | **Year Ended December 31, 2025** | **Year Ended December 31, 2025** | **Year Ended December 31, 2025** | **Year Ended December 31, 2025** | **Year Ended December 31, 2025** |
| | **Revenue** | **Gross margin** | **SG&A (1)** | **R&D (1)** | **Operating margin (2)** | **Income before income taxes** | **Income tax expense** | **Effective income tax rate** | **Diluted (loss) earnings per share from continuing operations** |
| GAAP Basis - Continuing Operations | $1992.7 | 56.2% | 36.1% | 7.3% | 5.9% | $24.6 | $(34.0) | (138.4)% | $1.31 |
| **Adjustments** |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Restructuring and optimization charges (A) |  | 0.9 |  |  | 2.1 | 42.6 | **6.9** |  | 0.81 |
| &nbsp;&nbsp;Impairment charges |  |  |  |  | 5.5 | 108.1 | 24.7 |  | 1.86 |
| &nbsp;&nbsp;Acquisition, integration and divestiture related items (B) |  | 3.5 | 1.5 |  | 2.0 | 40.3 | 19.1 |  | 0.48 |
| &nbsp;&nbsp;Separation costs |  |  |  |  | 0.2 | 4.8 | 1.1 |  | 0.08 |
| &nbsp;&nbsp;Other items (C) |  |  |  |  |  | 0.1 |  |  |  |
| &nbsp;&nbsp;Italian payback measure (D) | (9.0) | (0.1) | 0.2 |  | (0.3) | (9.0) | (0.9) |  | (0.18) |
| &nbsp;&nbsp;ERP implementation |  |  | (1.0) |  | 1.0 | 19.6 | 3.3 |  | 0.36 |
| &nbsp;&nbsp;MDR |  |  |  | (0.2) | 0.2 | 4.3 | 0.1 |  | 0.09 |
| &nbsp;&nbsp;Intangible amortization expense |  | 3.2 | (2.9) |  | 6.1 | 121.7 | 15.7 |  | 2.37 |
| &nbsp;&nbsp;Tax adjustments |  |  |  |  |  |  | 8.8 |  | (0.20) |
| &nbsp;&nbsp;Adjustments total | (9.0) | 7.5 | (2.2) | (0.2) | 16.8 | 332.5 | 78.8 |  | 5.67 |
| **Adjusted basis** | **$1983.7** | **63.7%** | **33.9%** | **7.1%** | **22.7%** | **$357.1** | **$44.8** | **12.6%** | **$6.98** |

---

------

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** |
| | **Revenue** | **Gross margin** | **SG&A (1)** | **R&D (1)** | **Operating margin (2)** | **Income before income taxes** | **Income tax expense** | **Effective income tax rate** | **Diluted earnings per share from continuing operations** |
| GAAP Basis - Continuing Operations | $1699.5 | 61.0% | 47.5% | 6.4% | 6.1% | $26.3 | $(30.9) | (117.5)% | $1.21 |
| **Adjustments** |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Restructuring and optimization charges (A) |  | 0.8 |  |  | 1.9 | 24.1 | 4.1 |  | 0.42 |
| &nbsp;&nbsp;Impairment charges |  |  |  |  |  | 7.9 | 0.5 |  | 0.15 |
| &nbsp;&nbsp;Acquisition, integration and divestiture related items (B) |  |  | (1.1) |  | 1.1 | 18.1 | 0.5 |  | 0.37 |
| &nbsp;&nbsp;Other items (C) |  |  | (0.2) |  | 0.1 | 0.9 | 0.2 |  | 0.02 |
| &nbsp;&nbsp;Italian payback measure (D) | 6.2 | 0.2 |  |  | 0.3 | 6.2 |  |  | 0.13 |
| &nbsp;&nbsp;ERP implementation |  |  | (0.7) |  | 0.7 | 12.7 | 1.8 |  | 0.23 |
| &nbsp;&nbsp;MDR |  |  |  | (0.3) | 0.3 | 4.6 |  |  | 0.10 |
| &nbsp;&nbsp;Pension termination costs |  | 0.2 | (8.0) |  | 8.2 | 139.6 | 58.4 |  | 1.73 |
| &nbsp;&nbsp;Intangible amortization expense |  | 3.5 | (2.8) |  | 6.3 | 108.8 | 11.9 |  | 2.06 |
| &nbsp;&nbsp;Tax adjustments |  |  |  |  |  |  | 0.2 |  |  |
| &nbsp;&nbsp;Adjustments total | 6.2 | 4.7 | (12.8) | (0.3) | 18.9 | 322.9 | 77.6 |  | 5.21 |
| **Adjusted basis** | **$1705.7** | **65.7%** | **34.7%** | **6.1%** | **25.0%** | **$349.2** | **$46.7** | **13.4%** | **$6.42** |

---

Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of as reported and adjusted revenues.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Operating margin defined as Income from continuing operations before interest and taxes as a percentage of as reported and adjusted revenues.

Totals may not sum due to rounding.

**Tickmarks to Reconciliation Tables**

***(A)*Restructuring and optimization charges –** For the three months ended December 31, 2025, pre-tax restructuring charges were $20.2 million, restructuring related charges were $3.5 million, and product optimization charges were $0.6 million. For the three months ended December 31, 2024, pre-tax restructuring charges were $3.3 million and restructuring related charges were $4.3 million. For the year ended December 31, 2025, pre-tax restructuring charges were $24.5 million, restructuring related charges were $15.0 million, and product optimization charges were $3.2 million. For the year ended December 31, 2024, pre-tax restructuring charges were $9.6 million and restructuring related charges were $14.5 million.

***(B)*Acquisition, integration and divestiture related items –** For the three months ended December 31, 2025, these charges primarily related to the acquisition the Vascular Intervention business of BIOTRONIK SE & Co. KG. For the three months ended December 31, 2025, the charges include inventory step-up costs of $26.9 million and integration and acquisition costs of $10.2 million. For the year ended December 31, 2025, these charges primarily related to the acquisition the Vascular Intervention business of BIOTRONIK SE & Co. KG and changes in the estimated fair value of our contingent consideration liabilities. For the year ended December 31, 2025, the charges include inventory step-up costs of $69.0 million, acquisition and integration costs of $36.7 million, and contingent consideration costs of $16.4 million, which were partially offset by a benefit of $82.2 million related to non-

------

designated foreign currency forward contracts entered into to economically hedge against the foreign currency exposure associated with the cash consideration required to complete the acquisition. For the three months and year ended December 31, 2024, these charges related to changes in the estimated fair value of our contingent consideration liabilities and the acquisition of Palette Life Sciences AB.

***(C)*Other -** For the year ended December 31, 2025, other items included expenses associated with prior year tax matters.

***(D)*Italian payback measure –** Adjustment reflects a $9.0 million favorable adjustment pertaining to amounts reserved for prior years recognized in the year ended December 31, 2025 compared to an unfavorable adjustment pertaining to amounts reserved for prior years of $6.2 million in the year ended December 31, 2024 and its impact on the adjusted basis for each Non-GAAP financial measure presented within the table.

------

**ABOUT TELEFLEX INCORPORATED**

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

**CAUTION CONCERNING FORWARD-LOOKING INFORMATION**

This press release contains forward-looking statements, including, but not limited to, forecasted 2026 GAAP, adjusted and pro forma adjusted constant currency revenue and revenue growth and GAAP and adjusted diluted earnings per share; our estimates regarding the projected impact of foreign currency exchange rate fluctuations on our 2026 financial results; statements about the pending Strategic Divestitures, the expected timetable for completing the Strategic Divestitures and the future financial and operating performance of the company following completion of the Strategic Divestitures; statements regarding our intended use of the net proceeds from the Strategic Divestitures; statements about the restructuring program associated with the Strategic Divestitures; and statements regarding our ability to drive durable performance and long-term value for shareholders. Actual results could differ materially from those in the forward-looking statements due to, among other things, unanticipated difficulties and expenditures in connection with integration programs; the possibility that the Strategic Divestitures do not close; unanticipated costs and length of time required to comply with legal requirements and regulatory approvals applicable to the Strategic Divestitures; customer and shareholder reaction to the Strategic Divestitures; disruption from the Strategic Divestitures that may make it more difficult to maintain business and operational relationships; significant transaction costs; delays or cancellations in shipments; demand for and market acceptance of new and existing products; our inability to provide products to our customers, which may be due to, among other things, events that impact key distributors, suppliers and third-party vendors that sterilize our products; our inability to effectively execute our restructuring plans and programs; our inability to realize anticipated savings from restructuring plans and programs; the impact of healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of enacted tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, tariffs, sovereign debt issues and international conflicts and hostilities, such as the ongoing conflicts in the Ukraine and the Middle East; public health epidemics; difficulties in entering new markets; general economic conditions; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our most recently filed Annual Report on Form 10-K. We expressly disclaim any obligation to update forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.

------

**TELEFLEX INCORPORATED**

**CONSOLIDATED STATEMENTS OF INCOME**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Twelve Months Ended** | **Twelve Months Ended** |
| | **December 31, 2025** | **December 31, 2024** | **December 31, 2025** | **December 31, 2024** |
| | **(Dollars and shares in thousands, except per share)** | **(Dollars and shares in thousands, except per share)** | **(Dollars and shares in thousands, except per share)** | **(Dollars and shares in thousands, except per share)** |
| Net revenues | $568984 | $442010 | $1992713 | $1699546 |
| Cost of goods sold | 261537 | 173222 | 871959 | 662159 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 307447 | 268788 | 1120754 | 1037387 |
| Selling, general and administrative expenses | 222368 | 178141 | 720169 | 674520 |
| Research and development expenses | 48737 | 29200 | 144781 | 109021 |
| Pension settlement charge |  |  |  | 132732 |
| Restructuring charges, separation costs and impairment charges | 22468 | 9045 | 137431 | 17463 |
| Income from continuing operations before interest and taxes | 13874 | 52402 | 118373 | 103651 |
| Interest expense | 28150 | 18658 | 100223 | 83513 |
| Interest income | (1854) | (1755) | (6403) | (6152) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income from continuing operations before taxes | (12422) | 35499 | 24553 | 26290 |
| (Benefit) taxes on income from continuing operations | (8870) | (394) | (33977) | (30901) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income from continuing operations | (3552) | 35893 | 58530 | 57191 |
| Operating (loss) income from discontinued operations | (865655) | (162253) | (1097174) | 48555 |
| (Benefit) taxes on operating loss from discontinued operations | (154878) | 10296 | (133004) | 36071 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Loss) income from discontinued operations | (710777) | (172549) | (964170) | 12484 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income | $(714329) | $(136656) | $(905640) | $69675 |
| Earnings per share: |  |  |  |  |
| Basic: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Loss) income from continuing operations | $(0.08) | $0.77 | $1.31 | $1.22 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income (loss) from discontinued operations | (16.07) | (3.72) | (21.61) | 0.27 |
| Net (loss) income  | $(16.15) | $(2.95) | $(20.30) | $1.49 |
| Diluted: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Loss) income from continuing operations | $(0.08) | $0.77 | $1.31 | $1.21 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss from discontinued operations | (16.07) | (3.70) | (21.56) | 0.27 |
| Net (loss) income  | $(16.15) | $(2.93) | $(20.25) | $1.48 |
| Weighted average common shares outstanding |  |  |  |  |
| Basic | 44238 | 46373 | 44622 | 46837 |
| Diluted | 44238 | 46619 | 44724 | 47094 |

---

------

**TELEFLEX INCORPORATED**

**CONSOLIDATED BALANCE SHEETS**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2024** |
| | **(Dollars in thousands)** | **(Dollars in thousands)** |
| **ASSETS** | | |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $378564 | $247852 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 345583 | 226733 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | 404395 | 306766 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 150678 | 101788 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid taxes | 19566 | 3457 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current assets of discontinued operations | 639552 | 584528 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 1938338 | 1471124 |
| Property, plant and equipment, net | 498281 | 308461 |
| Operating lease assets | 91817 | 95714 |
| Goodwill | 2305050 | 1992178 |
| Intangibles assets, net | 1524150 | 1348420 |
| Deferred tax assets | 12593 | 9285 |
| Other assets | 112984 | 100745 |
| Non-current assets of discontinued operations | 464026 | 1771987 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $6947239 | $7097914 |
| **LIABILITIES AND EQUITY** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current borrowings | $100000 | $100000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 130201 | 97858 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | 117350 | 107979 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payroll and benefit-related liabilities | 124769 | 101691 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued interest | 5404 | 5338 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | 18787 | 41163 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | 137195 | 59049 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current liabilities of discontinued operations | 128320 | 136282 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 762026 | 649360 |
| Long-term borrowings | 2541449 | 1555871 |
| Deferred tax liabilities | 183749 | 295455 |
| Noncurrent liability for uncertain tax positions | 3536 | 1831 |
| Noncurrent operating lease liabilities | 84210 | 87958 |
| Other liabilities | 194532 | 118436 |
| Non-current liabilities of discontinued operations | 52969 | 110863 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 3822471 | 2819774 |
| Commitments and contingencies |  |  |
| Shareholders' equity |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common shares, $1 par value Issued: 2025 — 48,197 shares; 2024 — 48,046 shares | 48197 | 48096 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 815813 | 781184 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 3149760 | 4115870 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (239468) | (316669) |
|  | 3774302 | 4628481 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: Treasury stock, at cost | 649534 | 350341 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total shareholders' equity | 3124768 | 4278140 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and shareholders' equity | $6947239 | $7097914 |

---

------

**TELEFLEX INCORPORATED**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **Year Ended** | **Year Ended** |
| | **December 31, 2025** | **December 31, 2024** |
| | **(Dollars in thousands)** | **(Dollars in thousands)** |
| Cash flows from operating activities of continuing operations: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income | $(905640) | $69675 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss (income) from discontinued operations | 964170 | (12484) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation expense | 56082 | 52754 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible asset amortization expense | 121656 | 108780 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred financing costs and debt discount amortization expense | 4675 | 3415 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on non-designated foreign currency forward contracts | (82636) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension settlement charge |  | 132732 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in contingent consideration | 16446 | 10027 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asset impairments | 108117 | 7834 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 25695 | 25960 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes, net | (100967) | (113207) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest benefit on swaps designated as net investment hedges | (22220) | (17410) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | (7608) | 13525 |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities, net of effects of acquisitions and disposals: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (85533) | (3603) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | 84041 | 6746 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | (35585) | 41906 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable, accrued expenses and other liabilities | (8284) | 2346 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes | (35727) | (27114) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities from continuing operations | 96682 | 301882 |
| Cash flows from investing activities of continuing operations: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Expenditures for property, plant and equipment | (95236) | (90437) |
| &nbsp;&nbsp;&nbsp;&nbsp;Payments for businesses and intangibles acquired, net of cash acquired | (831857) | (120) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds on non-designated balance sheet hedges | 82203 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sales of business and assets | 6712 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Insurance settlement proceeds | 9447 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net interest proceeds on swaps designated as net investment hedges | 21078 | 27196 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sales of investments |  | 7300 |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchase of investments | (5000) | (7300) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities from continuing operations | (812653) | (63361) |
| Cash flows from financing activities of continuing operations: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from new borrowings | 1140000 | 130000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Reduction in borrowings | (153000) | (291500) |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt extinguishment, issuance and amendment fees | (4961) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of common stock | (300000) | (200000) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net proceeds from share based compensation plans and the related tax impacts | 7167 | 3352 |
| &nbsp;&nbsp;&nbsp;&nbsp;Payments for contingent consideration | (15505) | (236) |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividends paid | (60268) | (63541) |
| &nbsp;&nbsp;&nbsp;&nbsp;Excise tax paid on repurchase of common stock | (1894) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) financing activities from continuing operations | 611539 | (421925) |
| Cash flows from discontinued operations: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 243995 | 333856 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (36538) | (35997) |
| Net cash provided by (used in) discontinued operations | 207457 | 297859 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents | 23174 | (9654) |
| Net increase (decrease) in cash, cash equivalents and restricted cash equivalents | 126199 | 104801 |
| Cash, cash equivalents and restricted cash equivalents at the beginning of the year | 327649 | 222848 |
| Less: Cash, cash equivalents and restricted cash of discontinued operations | (51168) | (42335) |
| Cash, cash equivalents and restricted cash equivalents at the end of the year | $402680 | $285314 |

---

------

**Contacts:**

Teleflex Incorporated:

Lawrence Keusch

Vice President, Investor Relations and Strategy Development

investors.teleflex.com

610-948-2836

## Exhibit 99.2

![](exhibit992to2-26x2026re2001.jpg)

Year-End 2025 Earnings Conference Call 2/26/2026 Teleflex Incorporated Exhibit 99.2

------

![](exhibit992to2-26x2026re2002.jpg)

The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) An audio replay of the call will be available beginning at 11:00 am Eastern Time on February 26, 2026 either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S.) or 1 609 800 9909 (all other locations). The confirmation code is 69028. Conference Call Logistics

------

![](exhibit992to2-26x2026re2003.jpg)

Today's Speakers TELEFLEX EARNINGS CONFERENCE CALL 2/26/2026 Lawrence Keusch VP, Investor Relations and Strategy Development Stuart Randle Interim President and CEO John Deren Executive VP and CFO

------

![](exhibit992to2-26x2026re2004.jpg)

TELEFLEX EARNINGS CONFERENCE CALL 2/26/20264 Additional Notes This document contains certain highlights with respect to our year end 2025 results and developments and does not purport to be a complete summary thereof. Accordingly, we encourage you to read our Earnings Release for the quarter ended December 31, 2025 located in the investor section of our website at www.teleflex.com and our Annual Report on Form 10-K for the year ended December 31, 2025 to be filed with the Securities and Exchange Commission. Unless otherwise noted, the following slides reflect continuing operations. This presentation contains forward-looking statements, including, but not limited to, our forecasted 2026: GAAP, pro forma adjusted revenue and pro forma adjusted constant currency revenue growth, GAAP and adjusted operating margin and GAAP and adjusted earnings per share and, in each case, our estimates with respect to the items expected to impact those forecasted results; statements with respect to our expectations with respect to the timing for closing of the sales of our Acute Care, Interventional Urology and OEM businesses (which we refer to as the "Strategic Divestitures"); statements regarding our planned uses of the net proceeds from the Strategic Divestitures, including, without limitation, with respect to the paydown of debt and the repurchase of shares our outstanding common stock; statements regarding projected costs, savings and timing with respect to restructuring activities related to the Strategic Divestitures; our expectation that our 2027 results will provide a more representative view of our standalone, steady-state financial profile; and other matters which inherently involve risks and uncertainties which could cause actual results to differ from those projected or implied in the forward– looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. We expressly disclaim any obligation to update these forward-looking statements, except as otherwise explicitly stated by us or as required by law or regulation. You should not place undue reliance on these statements or the scientific data presented. Note on Forward-Looking Statements Note on Non-GAAP Financial Measures This presentation refers to certain non-GAAP financial measures, including, but not limited to, pro forma adjusted revenue, pro forma adjusted constant currency revenue growth, adjusted diluted earnings per share, adjusted gross and operating margins and adjusted tax rate. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Tables reconciling these non-GAAP financial measures to the most comparable GAAP financial measures are contained within this presentation and the appendices at the end of this presentation.

------

![](exhibit992to2-26x2026re2005.jpg)

Stuart Randle Interim President and CEO Executive Overview

------

![](exhibit992to2-26x2026re2006.jpg)

– We have identified a number of transient factors related to our Strategic Divestitures that will impact 2026 results, including: – We expect 2027 results to provide a more representative view of our standalone, steady-state financial profile 2026 will be a transition year for Teleflex as we anticipate closing our announced Strategic Divestitures in the second half of the year and using the $1.8 billion in after-tax proceeds to return capital to shareholders via share repurchases and debt repayment 6 2027 Establishes Our Normalized, Steady-State Financial Profile – We will incur approximately $90 million of stranded costs associated with the reclassification to discontinued operations throughout 2026, which are necessary to support both continuing and discontinued operations for a transitionary period of time – Upon closing of the Strategic Divestitures, transition services ("TS") and manufacturing services ("MS") agreements will go into effect, which are expected to fully offset the $90 million stranded costs on an annualized basis beginning in 2027 – We anticipate eliminating ~$50 million of costs by mid-2028 through announced restructuring programs – Also upon closing of the Strategic Divestitures, we intend to use the transaction proceeds to repurchase $1 billion of our common stock and repay ~$800 million of debt, driving meaningfully lower share count and interest expense beginning in 2027

------

![](exhibit992to2-26x2026re2007.jpg)

2025 Performance Summary ◦ Pro forma adjusted constant currency revenue growth guidance range of 4.50% to 5.50% ◦ Adjusted diluted EPS from continuing operations guidance of $6.25 to $6.55 ◦ 2H'25 pro forma adjusted constant currency revenue grew 4.7% year-over-year ◦ 2025 adjusted gross margin of 63.7% and adjusted operating margin of 22.7% ◦ 2025 adjusted EPS of $6.98, an 8.7% increase year-over-year 2025 Continuing Operations Highlights 2026 Financial Guidance Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information. TELEFLEX EARNINGS CONFERENCE CALL 2/26/2026

------

![](exhibit992to2-26x2026re2008.jpg)

2H'25 Global Product Commentary of Continuing Operations TELEFLEX EARNINGS CONFERENCE CALL 2/26/20268 Vascular Interventional Sales ($M) Commentary • In 2H'25 growth was primarily driven by our central access, hemostatic, and atomization products Surgical • Excluding the impact of the Vascular Intervention acquisition, Interventional revenues increased double- digits year-over-year • The strong performance for the second half was driven by our broad Interventional portfolio, including growth drivers such as complex catheters and OnControl • Reported Vascular Intervention revenues were $202 million in 2H'25 $472.71 Reported rev. growth: 4.2% Pro forma adj. const. curr. rev. growth: 2.4% Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information. Pro forma adjusted constant currency revenue growth is as compared to the prior year period. 1. Revenue shown as pro forma adjusted $427.51 Reported rev. growth: 113.4% Pro forma adj. const. curr. rev. growth: 8.1% $219.31 Reported rev. growth: 4.4% Pro forma adj. const. curr. rev. growth: 3.2% • Underlying trends in the core Surgical franchise continue to be solid with strong strong double-digit growth from the majority of our franchises, offset by the expected impact of volume-based procurement in China

------

![](exhibit992to2-26x2026re2009.jpg)

John Deren Executive VP and CFO Financial Overview

------

![](exhibit992to2-26x2026re2010.jpg)

2025 Financial Review of Continuing Operations TELEFLEX EARNINGS CONFERENCE CALL 2/26/202610 Note: See appendices for reconciliations of non-GAAP financial information. SG&A Expense (% of Sales) Gross Margin R&D Expense (% of Sales) Operating Margin Earnings per Share ◦ negative impact of tariffs ◦ addition of the Vascular Intervention business, which has slightly lower gross margins compared to the corporate average ◦ negative impact of logistics and distribution costs and foreign exchange rates ◦ gross margin pressure ◦ higher operating expenses associated with the Vascular Intervention acquisition ◦ negative impact of foreign exchange rates ◦ higher revenue and operating income ◦ lower tax rate and share count ◦ partially offset by negative impact of interest expense and foreign exchange ◦ The year-over-year adjusted operating margin decline was driven by the following: ◦ The year-over-year adjusted gross margin decline was driven by the following: ◦ The year-over-year adjusted earnings per share increase was driven by the following: ◦ cost containment initiatives ◦ partially offset by the negative impact of foreign exchange rates ◦ The year-over-year adjusted SG&A expense % of sales decline was driven by the following: ◦ higher R&D expenses associated primarily with the Vascular Intervention acquisition ◦ The year-over-year adjusted R&D expense % of sales increase was driven by the following: (200) bps (230) bps +8.7% Adjusted GAAP

------

![](exhibit992to2-26x2026re2011.jpg)

11 Revenue ◦ 2026 GAAP revenue from continuing operations growth in the range of 14.4% to 15.4% year-over-year ◦ 2026 pro forma adjusted constant currency revenue growth in the range of 4.5% to 5.5% Earnings Per Share ◦ 2026 GAAP EPS from continuing operations in the range of $2.90 to $3.20 ◦ 2026 Adjusted diluted EPS from continuing operations in the range of $6.25 to $6.55 2026 Financial Guidance Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information.

------

![](exhibit992to2-26x2026re2012.jpg)

2026 Guidance Considerations 12 Pro Forma Adj. CC Revenue Growth ◦ 4.5% to 5.5% pro forma adjusted constant currency revenue growth for 2026 Adjusted Earnings Per Share ◦ 2026 adjusted EPS from continuing operations in the range of $6.25 to $6.55 ◦ Excludes foreign exchange, Italian payback matter, and discontinued products ◦ Includes Vascular Intervention revenue for the first half of 2025 ◦ ~19.0% adjusted operating margin ◦ Annualized impact of $90 million in stranded costs ◦ $105M of interest expense ◦ Refinancing of $500M (4.625% interest rate) debt ◦ No incremental debt paydown with net proceeds from sale transactions ◦ ~13.5% tax rate ◦ No material change in share count vs. 2025 ◦ No incremental share repurchase from net proceeds from sale transactions ◦ Assumes: Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information.

------

![](exhibit992to2-26x2026re2013.jpg)

13 Adjusted Operating Margin ◦ $90m stranded costs impacting 2026 adjusted operating margin Debt Paydown ◦ Intend to pay down ~$800 million in debt, including debt associated with the Vascular Intervention acquisition, funded with net proceeds from the sale transactions Share Repurchase ◦ $1 billion share repurchase authorization primarily funded with net proceeds from the sale transactions 2026 Financial Guidance – Future Opportunities ◦ TS/MS agreements expected to offset stranded costs on an annualized basis ◦ Announced restructuring programs to result in ~$50 million of pre-tax savings on an annualized basis, which will contribute to mitigating stranded costs

------

![](exhibit992to2-26x2026re2014.jpg)

2026 Financial Guidance of Continuing Operations Summary TELEFLEX EARNINGS CONFERENCE CALL 2/26/202614 2026 Guidance Low High GAAP Revenue Growth 14.4% 15.4% Impact of Vascular Intervention Pro Forma 10.0% 10.0% Impact of Discontinued Product (0.7)% (0.7)% Impact of Italian Payback Measure (0.5)% (0.5)% Base Year Adjustment (GAAP Versus Pro Forma Adjusted) 0.4% 0.4% Impact of Foreign Exchange Rate Fluctuations 0.7% 0.7% Pro Forma Constant Currency Revenue Growth 4.5% 5.5% Adjusted Operating Margin ~19% Adjusted EPS $6.25 $6.55 Adjusted EPS % Growth (10.5)% (6.2)% Note: See appendices for reconciliations of non-GAAP financial information.

------

![](exhibit992to2-26x2026re2015.jpg)

Forecasted 2026 Adjusted Constant Currency Revenue Growth From Continuing Operations Reconciliation TELEFLEX EARNINGS CONFERENCE CALL 2/26/202615 2026 Guidance 2025 2026 Guidance Low High GAAP revenue $1,992.7 $2,280 $2,300 % growth 14.4% 15.4% Vascular Intervention pro forma adjustment 199.0 — — Discontinued product adjustment (14.3) — — Italian payback measure adjustment (9.0) — — Pro forma constant currency revenue $2,168.4 $2,280 $2,300 % growth 5.1% 6.1% Base year adjustment (GAAP versus pro forma adjusted) 0.1% 0.1% % growth 5.2% 6.2% Estimated impact of foreign currency exchange rate fluctuations (0.7)% (0.7)% % pro forma adjusted constant currency growth 4.5% 5.5% Note: See appendices for reconciliations of non-GAAP financial information.

------

![](exhibit992to2-26x2026re2016.jpg)

TELEFLEX EARNINGS CONFERENCE CALL 2/26/202616 Key Takeaways Teleflex is in the midst of a transformation that • optimizes our portfolio • creates a more focused medical technologies leader • and positions our company for meaningful value creation opportunities going forward. It is energizing to see how focused and committed our team has been to delivering for customers, patients, and shareholders. RemainCo delivered solid pro forma adjusted constant currency growth of 4.7% year-over- year in 2H'25, which is • inclusive of the negative impact from volume-based procurement in China • and reflects the period in which we owned the Vascular Intervention business. Paired with our 2026 pro-forma constant currency revenue growth guidance of 4.5% to 5.5%, aligns with our mid-single-digit growth profile and represent a strong reflection of the stable growth potential of our go-forward business. The two sales transactions remain on track to close in 2H'26, and we remain committed to using the majority of the associated after-tax proceeds to • return significant capital to shareholders through our $1 billion share repurchase program • while also reducing debt to enhance our financial flexibility and support future growth and value creation. Upon closing, we expect to recognize at least $90 million of TS and MS revenue, fully offsetting stranded costs on an annualized basis. We are also engaged in reducing costs with today's announced restructuring initiative targeting approximately $50 million in savings. We expect financial performance to improve through 2026, with more meaningful adjusted EPS growth in 2027 and beyond.

------

![](exhibit992to2-26x2026re2017.jpg)

TELEFLEX EARNINGS CONFERENCE CALL 2/26/202617 Thank You!

------

![](exhibit992to2-26x2026re2018.jpg)

Appendices

------

![](exhibit992to2-26x2026re2019.jpg)

The presentation to which these appendices are attached and the following appendices include, among other things, tables reconciling the following applicable non-GAAP financial measures to the most comparable GAAP financial measure: Adjusted revenue. This non-GAAP measure is based upon net revenues, adjusted to exclude the impact of adjustments in our reserves and the corresponding revenue impact related to the Italian payback measure. The Italian payback measure is a law that requires suppliers of medical devices to the Italian National Healthcare System to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. As a result of a ruling from the Italian courts, we recognized a decrease in our reserves during the year ended December 31, 2024, of which $13.8 million related to prior years when including discontinued operations and $6.2 million on a continuing operations basis. In August 2025, the Italian Parliament enacted a modification to the previously enacted legislation that reduced the payment amounts due from the affected companies, including Teleflex, to approximately 25% of the amounts originally invoiced for the years 2015 through 2018. Payment of the reduced amount precludes the pursuit of further legal action related to the obligation to pay the amounts relating to such years. During the third quarter of 2025, we remitted payment to the related regions to settle the years 2015 through 2018. As a result of the modification in the legislation, along with an adjustment to our calculation of the reserves related to years 2019 through 2025, we recognized a $23.7 million decrease in our reserve (and corresponding increase to revenue for the three months and year ended December 31, 2025), of which $20.1 million pertains to prior periods when including discontinued operations and $9.0 million on a continuing operations basis. The amounts do not represent normal adjustments to revenue and are nonrecurring in nature, making it difficult to contribute to a meaningful evaluation of our period over period operating performance. Accordingly, management has excluded the $9.0 million favorable adjustment recognized in the current period and the unfavorable adjustment of $6.2 million in the prior period. Adjusted constant currency revenue growth. This non-GAAP measure is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends. Pro forma adjusted revenue. This non-GAAP measure is based upon net revenues, adjusted to (i) exclude, depending on the period presented, the impact of adjustments in our reserves and the corresponding revenue impact related to the Italian payback measure described in Adjusted revenue and approximately $14 million of products discontinued in the year ended December 31, 2025 due to a strategic realignment; and (ii) include revenues for the six months ended June 29, 2025 generated by the Vascular Intervention business we acquired from BIOTRONIK SE & Co. KG. Pro forma adjusted constant currency revenue growth. This non-GAAP measure is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Pro forma adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends. Non-GAAP Financial Measures TELEFLEX EARNINGS CONFERENCE CALL 2/26/202619

------

![](exhibit992to2-26x2026re2020.jpg)

Adjusted diluted earnings per share. This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the impact of (i) restructuring and optimization charges; (ii) impairment charges; (iii) acquisition, integration and divestiture related items; (iv) separation costs; (v) Italian payback measure; (vi) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (vii) pension termination and related charges; (viii) certain costs associated with the registration of medical devices under the European Union Medical Device Regulation; (ix) intangible amortization expense; and (x) tax adjustments. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends. Adjusted gross profit and margin. These measures exclude, depending on the period presented, the impacts of (i) restructuring and optimization charges; (ii) acquisition, integration and divestiture related items, (iii) pension termination and related charges, (iv) intangible amortization expense, and (v) Italian payback measure. Adjusted operating profit and margin. These measures exclude, depending on the period presented, the impact of (i) restructuring and optimization charges; (ii) impairment charges; (iii) acquisition, integration and divestiture related items; (iv) separation costs; (v) Italian payback measure; (vi) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (vii) pension termination and related charges; (viii) certain costs associated with the registration of medical devices under the European Union Medical Device Regulation; (ix) and intangible amortization expense. Adjusted tax rate. This measure is the percentage of the Company's adjusted taxes on income from continuing operations to its adjusted income from continuing operations before taxes. Adjusted taxes on income from continuing operations excludes, depending on the period presented, the impact of tax benefits or costs associated with (i) restructuring and optimization charges; (ii) impairment charges; (iii) acquisition, integration and divestiture related items; (iv) separation costs; (v) Italian payback measure; (vi) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (vii) certain costs associated with the registration of medical devices under the European Union Medical Device Regulation; (viii) intangible amortization expense; and (ix) tax adjustments. Non-GAAP Financial Measures TELEFLEX EARNINGS CONFERENCE CALL 2/26/202620

------

![](exhibit992to2-26x2026re2021.jpg)

The following is an explanation of certain of the adjustments that are applied with respect to one or more of the non-GAAP financial measures that appear in the presentation to which these appendices are attached: Restructuring and optimization charges - Restructuring and optimization charges include expenses associated with discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies, integrate acquired businesses and optimize product portfolios through targeted optimization efforts. These changes include qualified restructuring costs (which may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement), restructuring related (which may include accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of a restructuring program) and product line exit charges. Impairment charges - Impairment charges, including those related to goodwill, and other assets occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results. Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; temporary financing costs directly associated with the transaction, such as bridge loan financing fees, ticking fees, and similar charges, and the impact of derivative instruments executed to hedge foreign currency exposure or other risks associated with the purchase price. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities. Separation costs - These are expenses related to the Strategic Divestitures, including activities to prepare the businesses for divestiture and maintain continuity through the separation process. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur after the transaction and related transition services agreements and other arrangements negotiated in connection with the Strategic Divestitures have been completed. Italian payback measure - These adjustments represent the exclusion of adjustments in our reserves related to the Italian payback measure as described in Adjusted revenue. Other - These are discrete items that occur sporadically and can affect period-to-period comparisons. Non-GAAP Adjustments TELEFLEX EARNINGS CONFERENCE CALL 2/26/202621

------

![](exhibit992to2-26x2026re2022.jpg)

Pension termination and related charges - These adjustments represent charges associated with the planned termination of the Teleflex Incorporated Retirement Income Plan, a frozen U.S. defined benefit pension plan, and related direct incremental expenses including certain charges stemming from the liquidation of surplus plan assets. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur once the plan termination process has been completed. Accordingly, management has excluded these amounts to facilitate an evaluation of our current operating performance and a comparison to our past operating performance. European medical device regulation - The European Union ("EU") has adopted the EU Medical Device Regulation ("MDR"), which replaces the existing Medical Devices Directive ("MDD") and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post- market surveillance. The MDR requirements became effective in May 2021, although certain devices that previously satisfied MDD requirements can continue to be marketed in the EU until December 2027 for highest-risk devices and December 2028 for lower-risk devices, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices. As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD). Intangible amortization expense - Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions. ERP implementation - These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance. Tax adjustments - These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability. Non-GAAP Adjustments TELEFLEX EARNINGS CONFERENCE CALL 2/26/202622

------

![](exhibit992to2-26x2026re2023.jpg)

Appendix A1 – Pro Forma Adjusted Revenue by Global Product Category (Dollars in millions) TELEFLEX EARNINGS CONFERENCE CALL 2/26/202623 FY 2025 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Vascular 917.7 240.2 232.5 225.9 219.1 Interventional 647.8 217.9 215.9 113.8 100.2 Surgical 418.2 110.9 109.5 102.8 95.0 Other 9.0 — 9.0 — — GAAP revenue $1,992.7 $569.0 $566.9 $442.5 $414.3 Interventional - Vascular Intervention 199.0 — — 103.8 95.2 Interventional - Discontinued Products (12.3) (1.3) (5.0) (3.4) (2.6) Surgical - Discontinued Products (2.0) (0.4) (0.6) (0.5) (0.5) Other - Italian payback measure (9.0) — (9.0) — — Pro forma adjusted revenue $2,168.3 $567.3 $552.2 $542.4 $506.4 Vascular 917.7 240.2 232.5 225.9 219.1 Interventional 834.5 216.6 210.9 214.2 192.8 Surgical 416.1 110.5 108.8 102.3 94.5 Other — — — — — Note: See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions.

------

![](exhibit992to2-26x2026re2024.jpg)

Appendix A2 – Reconciliation of Pro Forma Adjusted Constant Currency Revenue Growth by Global Product Category TELEFLEX EARNINGS CONFERENCE CALL 2/26/202624 2H 2025 Q4 2025 Q3 2025 Reported Revenue Growth Currency Impact Adjustment Impact Pro Forma Adjusted Constant Currency Revenue Growth Reported Revenue Growth Currency Impact Adjustment Impact Pro Forma Adjusted Constant Currency Revenue Growth Reported Revenue Growth Currency Impact Adjustment Impact Pro Forma Adjusted Constant Currency Revenue Growth Vascular 4.2% (1.8)% —% 2.4% 5.6% (2.2)% —% 3.4% 2.7% (1.3)% —% 1.4% Interventional1 113.4 (2.8) (102.5) 8.1 108.7 (3.4) (97.1) 8.2 118.5 (2.2) (108.3) 8.0 Surgical2 4.4 (1.5) 0.3 3.2 0.6 (1.7) 0.4 (0.7) 8.4 (1.1) 0.2 7.5 Total Continuing Operations3 30.8% (2.0)% 24.1% 4.7% 28.7% (2.4)% 22.0% 4.3% 33.0% (1.5)% 26.5% 5.0% Note: See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions. 1. Adjustments are inclusive of Vascular Intervention pro forma and discontinued product adjustments for all periods presented 2. Adjustments are inclusive of discontinued product adjustments for all periods presented 3. Adjustments are inclusive of Vascular Intervention pro forma, Italian payback measure, and discontinued product adjustments for all periods presented

------

![](exhibit992to2-26x2026re2025.jpg)

Appendix A3 – Reconciliation of Revenues (Dollars in millions) TELEFLEX EARNINGS CONFERENCE CALL 2/26/202625 December 31, 2025 GAAP revenue including discontinued operations $3,297.0 Discontinued operations (1,304.3) Continuing operations 1,992.7 Italian payback measure adjustment (9.0) Continuing operations as adjusted $1,983.7 Note: See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions.

------

![](exhibit992to2-26x2026re2026.jpg)

Appendix B1 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) TELEFLEX EARNINGS CONFERENCE CALL 2/26/202626 Three Months Ended December 31, 2025 Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) (Loss) Income before income taxes Income tax expense Effective income tax rate Diluted (loss) earnings per share from continuing operations GAAP Basis $569.0 54.0% 39.1% 8.6% 2.4% $(12.4) $(8.9) 71.4% $(0.08) Adjustments Restructuring and optimization charges (A) — 0.7 — — 4.3 24.3 3.9 0.46 Acquisition, integration and divestiture related items (B) — 4.8 (1.9) — 6.7 37.6 6.8 0.69 Separation costs — — — — 0.4 2.2 1.1 0.03 ERP implementation — — (1.1) — 1.1 6.3 1.2 0.12 MDR — — — (0.3) 0.2 1.4 — 0.03 Intangible amortization expense — 3.3 (3.1) — 6.4 36.7 4.8 0.72 Tax adjustments — — — — — — 1.7 (0.04) Adjustments total 8.8 (6.1) (0.3) 19.1 108.5 19.5 2.01 Adjusted basis $569.0 62.8% 33.0% 8.3% 21.5% $96.1 $10.6 11.1% $1.93 Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of as reported and adjusted revenues. (2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of as reported and adjusted revenues. See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions. Totals may not sum due to rounding.

------

![](exhibit992to2-26x2026re2027.jpg)

Three Months Ended December 31, 2024 Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations GAAP Basis $442.0 60.8% 40.3% 6.6% 11.9% $35.5 -$0.4 (1.1)% $0.77 Adjustments Restructuring and optimization charges (A) — 1.0 — — 3.0 7.6 1.2 0.14 Impairment charges — — — — — 5.7 — 0.12 Acquisition, integration and divestiture related items (B) — — (2.3) — 2.3 10.2 0.5 0.20 Other items (C) — (0.2) — 0.2 1.0 0.2 0.02 ERP implementation — — (0.8) — 0.8 3.5 0.4 0.07 MDR — — — (0.1) 0.1 0.4 — 0.01 Pension termination costs 0.6 (0.7) (0.2) 1.5 6.5 1.5 0.11 Intangible amortization expense — 3.4 (2.7) — 6.1 27.3 2.9 0.52 Tax adjustments — — — — — — 2.3 (0.05) Adjustments total 5.0 (6.7) (0.3) 14.0 62.2 9.0 1.14 Adjusted basis $442.0 65.8% 33.6% 6.3% 25.9% $97.7 $8.6 8.8% $1.91 TELEFLEX EARNINGS CONFERENCE CALL 2/26/202627 Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of net revenues. (2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of net revenues. See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions. Totals may not sum due to rounding. Appendix B2 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)

------

![](exhibit992to2-26x2026re2028.jpg)

Appendix B3 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) TELEFLEX EARNINGS CONFERENCE CALL 2/26/202628 Year Ended December 31, 2025 Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations GAAP Basis $1,992.7 56.2% 36.1% 7.3% 5.9% $24.6 $(34.0) (138.4)% $1.31 Adjustments Restructuring and optimization charges (A) — 0.9 — — 2.1 42.6 6.9 0.81 Impairment charges — — — — 5.5 108.1 24.7 1.86 Acquisition, integration and divestiture related items (B) — 3.5 1.5 — 2.0 40.3 19.1 0.48 Separation costs — — — — 0.2 4.8 1.1 0.08 Other items (C) — — — — — 0.1 — — Italian payback measure (D) (9.0) (0.1) 0.2 — (0.3) (9.0) (0.9) (0.18) ERP implementation — — (1.0) — 1.0 19.6 3.3 0.36 MDR — — — (0.2) 0.2 4.3 0.1 0.09 Intangible amortization expense — 3.2 (2.9) — 6.1 121.7 15.7 2.37 Tax adjustments — — — — — — 8.8 (0.20) Adjustments total (9.0) 7.5 (2.2) (0.2) 16.8 332.5 78.8 5.67 Adjusted basis $1,983.7 63.7% 33.9% 7.1% 22.7% $357.1 $44.8 12.6% $6.98 Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of as reported and adjusted revenues. (2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of as reported and adjusted revenues. See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions. Totals may not sum due to rounding.

------

![](exhibit992to2-26x2026re2029.jpg)

Year Ended December 31, 2024 Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations GAAP Basis $1,699.5 61.0% 47.5% 6.4% 6.1% $26.3 $(30.9) (117.5)% $1.21 Adjustments Restructuring and optimization charges (A) — 0.8 — — 1.9 24.1 4.1 0.42 Impairment charges — — — — — 7.9 0.50 0.15 Acquisition, integration and divestiture related items (B) — — (1.1) — 1.1 18.1 0.5 0.37 Other items (C) — — (0.2) — 0.1 0.9 0.20 0.02 Italian payback measure (D) 6.2 0.2 — — 0.3 6.2 — 0.13 ERP implementation — — (0.7) — 0.7 12.7 1.8 0.23 MDR — — — (0.3) 0.3 4.6 — 0.10 Pension termination costs — 0.2 (8.0) — 8.2 139.6 58.4 1.73 Intangible amortization expense — 3.5 (2.8) — 6.3 108.8 11.9 2.06 Tax adjustments — — — — — — 0.2 — Adjustments total 6.2 4.7 (12.8) (0.3) 18.9 322.9 77.6 5.21 Adjusted basis $1,705.7 65.7% 34.7% 6.1% 25.0% $349.2 $46.7 13.4% $6.42 TELEFLEX EARNINGS CONFERENCE CALL 2/26/202629 Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of net revenues. (2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of net revenues. See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions. Totals may not sum due to rounding. Appendix B4 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)

------

![](exhibit992to2-26x2026re2030.jpg)

TELEFLEX EARNINGS CONFERENCE CALL 2/26/202630 A. Restructuring and optimization charges – For the three months ended December 31, 2025, pre-tax restructuring charges were $20.2 million, restructuring related charges were $3.5 million, and product optimization charges were $0.6 million. For the three months ended December 31, 2024, pre-tax restructuring charges were $3.3 million and restructuring related charges were $4.3 million. For the year ended December 31, 2025, pre-tax restructuring charges were $24.5 million, restructuring related charges were $15.0 million, and product optimization charges were $3.2 million. For the year ended December 31, 2024, pre-tax restructuring charges were $9.6 million and restructuring related charges were $14.5 million. B. Acquisition, integration and divestiture related items – For the three months ended December 31, 2025, these charges primarily related to the acquisition the Vascular Intervention business of BIOTRONIK SE & Co. KG. For the three months ended December 31, 2025, the charges include inventory step-up costs of $26.9 million and integration and acquisition costs of $10.2 million. For the year ended December 31, 2025, these charges primarily related to the acquisition the Vascular Intervention business of BIOTRONIK SE & Co. KG and changes in the estimated fair value of our contingent consideration liabilities. For the year ended December 31, 2025, the charges include inventory step-up costs of $69.0 million, acquisition and integration costs of $36.7 million, and contingent consideration costs of $16.4 million, which were partially offset by a benefit of $82.2 million related to non-designated foreign currency forward contracts entered into to economically hedge against the foreign currency exposure associated with the cash consideration required to complete the acquisition. For the three months and year ended December 31, 2024, these charges related to changes in the estimated fair value of our contingent consideration liabilities and the acquisition of Palette Life Sciences AB. C. Other - For the year ended December 31, 2025, other items included expenses associated with prior year tax matters. D. Italian payback measure – Adjustment reflects a $9.0 million favorable adjustment pertaining to amounts reserved for prior years recognized in the year ended December 31, 2025 compared to an unfavorable adjustment pertaining to amounts reserved for prior years of $6.2 million in the year ended December 31, 2024 and its impact on the adjusted basis for each Non-GAAP financial measure presented within the table. Appendix B Tickmarks

------

![](exhibit992to2-26x2026re2031.jpg)

Appendix C - 2026 Adj. Operating Margin Guidance Reconciliation TELEFLEX EARNINGS CONFERENCE CALL 2/26/202631 Forecasted GAAP Operating Margin 10.5% Estimated restructuring and optimization items 2.0% Estimated acquisition, integration and divestiture related items 1.9% Estimated other items (1.1)% Estimated ERP implementation 0.7% Estimated MDR 0.1% Estimated intangible amortization expense 4.9% Forecasted Adjusted Operating Margin 19.0%

------

![](exhibit992to2-26x2026re2032.jpg)

Appendix D - Reconciliation of Forecasted 2026 Adjusted Earnings Per Share Guidance TELEFLEX EARNINGS CONFERENCE CALL 2/26/202632 Low High Forecasted GAAP Diluted Earnings Per Share from continuing operations $2.90 $3.20 Restructuring and optimization items, net of tax $0.81 $0.81 Acquisition, integration and divestiture related items, net of tax $0.76 $0.76 Other costs, net of tax $(0.65) $(0.65) ERP implementation, net of tax $0.33 $0.33 MDR, net of tax $0.03 $0.03 Intangible amortization expense, net of tax $2.07 $2.07 Forecasted Adjusted Diluted Earnings Per Share from continuing operations, net of tax $6.25 $6.55

------

![](exhibit992to2-26x2026re2033.jpg)

Appendix E1 – Supplemental Historical Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) TELEFLEX EARNINGS CONFERENCE CALL 2/26/202633 Three Months Ended September 28, 2025 Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) (Loss) Income before income taxes Income tax expense Effective income tax rate Diluted (loss) earnings per share from continuing operations GAAP Basis $566.9 51.5% 36.6% 7.8% (11.0)% $(92.4) $(34.0) 36.8% $(1.32) Adjustments Restructuring and optimization charges (A) — 0.6 — — 0.9 4.8 0.8 0.08 Impairment charges — — — — 17.6 100.0 22.9 1.74 Acquisition, integration and divestiture related items (B) — 7.4 (1.1) (0.1) 8.6 48.7 9.4 0.88 Separation costs — — — — 0.2 1.3 0.1 0.03 Italian payback measure (D) (9.0) (0.6) 0.5 0.1 (1.2) (9.0) (0.9) (0.18) ERP implementation — — (0.6) — 0.6 3.6 0.6 0.07 MDR — — — (0.2) 0.2 1.3 — 0.03 Intangible amortization expense — 3.4 (2.7) — 6.1 34.3 4.7 0.67 Tax adjustments — — — — — — 5.0 (0.11) Adjustments total (9.0) 10.8 (3.9) (0.2) 33.0 185.0 42.6 3.21 Adjusted basis $557.9 62.3% 32.7% 7.6% 22.0% $92.6 $8.6 9.3% $1.89 Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of as reported and adjusted revenues. (2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of as reported and adjusted revenues. See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions. Totals may not sum due to rounding.

------

![](exhibit992to2-26x2026re2034.jpg)

Three Months Ended June 29, 2025 Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations GAAP Basis $442.5 60.1% 31.1% 6.0% 20.6% $70.7 $2.5 3.5% $1.54 Adjustments Restructuring and optimization charges (A) — 1.4 — — 1.7 7.4 1.2 0.14 Impairment charges — — — — 1.8 8.1 1.8 0.14 Acquisition, integration and divestiture related items (B) — — 6.4 — (6.4) (27.9) 2.1 (0.68) Separation costs — — — — 0.3 1.3 — 0.03 Other items (C) — — — — — 0.1 — — ERP implementation — — (0.9) — 0.9 3.8 0.5 0.07 MDR — — — (0.2) 0.2 0.9 — 0.02 Intangible amortization expense — 3.0 (2.7) — 5.7 25.1 3.0 0.50 Tax adjustments — — — — — — 1.4 (0.03) Adjustments total — 4.4 2.8 (0.2) 4.2 18.8 10.0 0.19 Adjusted basis $442.5 64.5% 33.9% 5.8% 24.8% $89.5 $12.5 14.1% $1.73 TELEFLEX EARNINGS CONFERENCE CALL 2/26/202634 Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of net revenues. (2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of net revenues. See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions. Totals may not sum due to rounding. Appendix E2 – Supplemental Historical Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)

------

![](exhibit992to2-26x2026re2035.jpg)

Appendix E3 – Supplemental Historical Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) TELEFLEX EARNINGS CONFERENCE CALL 2/26/202635 Three Months Ended March 30, 2025 Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations GAAP Basis $414.3 61.7% 36.9% 6.1% 18.3% $58.8 $6.4 10.9% $1.14 Adjustments Restructuring and optimization charges (A) — 1.1 — — 1.5 6.0 1.0 0.11 Acquisition, integration and divestiture related items (B) — — 4.4 — (4.4) (18.1) 0.8 (0.42) ERP implementation — — (1.4) — 1.4 5.9 1.0 0.11 MDR — — — (0.2) 0.2 0.7 — 0.02 Intangible amortization expense — 3.3 (2.9) — 6.2 25.6 3.1 0.49 Tax adjustments — — — — — — 0.7 (0.01) Adjustments total — 4.4 0.1 (0.2) 4.9 20.1 6.6 0.30 Adjusted basis $414.3 66.1% 37.0% 5.9% 23.2% $78.9 $13.0 16.4% $1.44 Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of as reported and adjusted revenues. (2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of as reported and adjusted revenues. See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions. Totals may not sum due to rounding.

------

![](exhibit992to2-26x2026re2036.jpg)

TELEFLEX EARNINGS CONFERENCE CALL 2/26/202636 A. Restructuring and optimization charges – For the three months ended September 28, 2025, pre-tax restructuring charges were $1.6 million and restructuring related charges were $3.3 million. For the three months ended June 29, 2025, pre-tax restructuring charges were $1.3 million, restructuring related charges were $3.5 million, and product optimization charges were $2.6 million. For the three months ended March 30, 2025, pre-tax restructuring charges were $1.4 million and restructuring related charges were $4.6 million. B. Acquisition, integration and divestiture related items – For the three months ended September 28, 2025 and June 29, 2025 these charges primarily related to the acquisition the Vascular Intervention business of BIOTRONIK SE & Co. KG and changes in the estimated fair value of our contingent consideration liabilities. For the three months ended September 28, 2025, the charges include inventory step-up costs of $42.1 million and integration and acquisition costs of $4.4 million. For the three months ended June 29, 2025 the charges include acquisition and integration costs of $15.8 million, which were offset by a benefit of $59.7 million related to non-designated foreign currency forward contracts. For the three months ended March 30, 2025, these charges primarily related to the pending acquisition of the Vascular Intervention business of BIOTRONIK SE & Co. KG, which is inclusive of $6.2 million of acquisition and integration costs offset by the recognition of a $22.5 million benefit related to non-designated foreign currency forward contracts. C. Other - For the three months ended June 29, 2025, other items included expenses associated with prior year tax matters. D. Italian payback measure – Adjustment reflects a $9.0 million favorable adjustment recognized in the three months ended June 29, 2025 and its impact on the adjusted basis for each Non-GAAP financial measure presented within the table. Appendix E Tickmarks

------